APOA4 Antibody (YA3672)

Apolipoprotein A-IV (apoA4) is a lipid-binding apolipoprotein primarily synthesized in the small intestine, where it is incorporated into nascent chylomicrons during dietary fat absorption and subsequently circulates in association with chylomicron remnants, high-density lipoproteins (HDL), or as a lipid-free protein^[1][2]. ApoA4 plays a central role in lipid absorption and lipoprotein metabolism by modulating triglyceride-rich lipoprotein assembly, promoting triglyceride secretion, facilitating reverse cholesterol transport, and activating lecithin:cholesterol acyltransferase-dependent pathways involved in HDL biogenesis^[1][2][3]. Mechanistically, apoA4 contributes to cholesterol efflux and limits the formation of oxidized low-density lipoprotein, thereby supporting anti-atherogenic lipid homeostasis^[1][2]. Beyond lipid metabolism, apoA4 participates in glucose homeostasis, food intake regulation, platelet function, and thrombosis control, highlighting its integration across metabolic and cardiovascular pathways^[1][2]. In disease-relevant models, apoA4 deficiency has been associated with atherosclerosis and diabetes, whereas exogenous or recombinant apoA4 exhibits anti-atherosclerotic, anti-thrombotic, anti-diabetic, and anti-inflammatory activities^[1][2][4]. Mechanistically, apoA4 suppresses vascular inflammation through DHCR24-dependent inhibition of NF-κB signaling, resulting in reduced endothelial expression of ICAM-1 and VCAM-1 in experimental models^[4]. Compared with the related isoform apoA-I, apoA4 displays distinct structural properties and has demonstrated superior anti-inflammatory efficacy in vascular inflammation models, indicating functional specialization among apolipoprotein family members^[4]. For experimental applications, recombinant apoA4 and apoA4-containing reconstituted HDL particles are widely used to investigate lipid metabolism, reverse cholesterol transport, thrombosis, and inflammatory signaling pathways^[1][4].